Karyopharm Discloses Nasdaq Inducement Grant Compliance

Karyopharm Therapeutics Inc. announced that it has received an inducement grant from Nasdaq under Listing Rule 5635(c)(4). The grant allows the company to remain listed on the Nasdaq Capital Market while it works to meet the exchange’s continued listing standards. Karyopharm indicated that it will use the additional time to address the specific compliance issues identified by Nasdaq, though the company did not disclose the exact nature of those deficiencies.

The Nasdaq grant is a temporary measure that provides listed companies with a grace period to rectify non‑compliance with requirements such as market value of listed securities, stockholder equity, or other financial metrics. Karyopharm’s filing states that it will submit a compliance plan and periodic updates to the exchange as part of the inducement terms. The company expects to achieve full compliance within the timeframe stipulated by Nasdaq, which typically ranges from 90 to 180 days depending on the issue.

For investors, the grant signals that Karyopharm’s listing status is not in immediate jeopardy, but the firm must still meet the exchange’s standards to avoid delisting. The situation may affect perceptions of the company’s financial health and could influence liquidity, as Nasdaq listing requirements are often viewed as a proxy for corporate stability.

Overall, the inducement grant provides Karyopharm a short‑term window to resolve compliance gaps while maintaining its public market presence, a factor that market participants will monitor alongside the company’s broader operational performance.